U.S. markets closed

Adverum Biotechnologies, Inc. (ADVM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
12.36+0.07 (+0.57%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close12.29
Open12.43
Bid12.30 x 800
Ask12.87 x 1100
Day's Range12.22 - 12.58
52 Week Range6.58 - 26.98
Volume612,831
Avg. Volume1,287,040
Market Cap1.203B
Beta (5Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-1.23
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 Virtual
    GlobeNewswire

    Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 Virtual

    \-- Dr. Carl Regillo to present OPTIC data at the Retina Subspecialty Day on Friday, November 13, 2020 at 2:15 pm PT \--\-- Company to host webcast with key opinion leaders on Saturday, November 14, 2020 at 7:30 am PT --REDWOOD CITY, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of additional clinical data for Cohorts 1-4 in the OPTIC Phase 1 clinical trial of ADVM-022 intravitreal injection gene therapy in wet age-related macular degeneration (wet AMD). This will be in the form of a live broadcast during the American Academy of Ophthalmology (AAO) 2020 Virtual Meeting.Presentation of New OPTIC Data: Event: Retina Subspecialty Day 2020 Virtual Meeting Title: Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD: OPTIC Phase 1 Study Date: November 13, 2020 Time: 2:15 pm PT Presenter: Carl Regillo, M.D., F.A.C.S, chief of retina services at Wills Eye Hospital Presentation: At the beginning of Dr. Regillo’s presentation, Adverum plans to issue a press release and post the new data presentation under Events and Presentations in the Investors section of the company’s website.Presentation of Existing OPTIC Data: Event: AAO 2020 Virtual Meeting Title: Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial Cohorts 1-4, from the August 10, 2020 data presentation) Date: November 14-17, 2020 Presenter: Arshad M. Khanani, M.D., M.A., managing partner and director of clinical research, Sierra Eye Associates, clinical associate professor of ophthalmology, University of Nevada Presentation: On or before November 13, 2020 the virtual presentations will be available on demand to AAO participants, and Adverum plans to post the presentation under Events and Presentations in the Investors section of the company’s website.Adverum Webcast: Date: November 14, 2020 Time: 7:30 – 9:00 am PT (10:30 am – 12:00 pm ET) Presenters: * Carl Regillo, M.D., F.A.C.S, chief of retina services at Wills Eye Hospital and investigator in the OPTIC Phase 1 trial * Steven Yeh, M.D., associate professor, director, section of uveitis and ocular immunology, Emory Eye Center * David S. Boyer, M.D., senior partner, Retina-Vitreous Associates Medical Group and adjunct clinical professor of ophthalmology, University of Southern California/ Keck School of Medicine, Los Angeles, investigator in the OPTIC Phase 1 trial The live video webcast will be accessible under Events and Presentations in the Investors section of the company's website. The archived audio webcast will be available on the Adverum website following the call and will be available for 30 days.On November 5, 2020 after market, Adverum plans to report recent business progress and financial results for the third quarter of 2020. The Company plans to host the KOL webcast on November 14, 2020 to review new OPTIC data instead of hosting a quarterly conference call this quarter.About Adverum Biotechnologies Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com. CONTACT: Investor and Media Inquiries: Myesha Lacy Vice President, Investor Relations and Corporate Communications Adverum Biotechnologies, Inc. mlacy@adverum.com 1-650-649-1257

  • Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?

    Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.

  • Adverum Biotechnologies, Inc. (ADVM) Is Stalling With Hedge Funds
    Insider Monkey

    Adverum Biotechnologies, Inc. (ADVM) Is Stalling With Hedge Funds

    The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index was trading around the […]